Analyst Price Target is $21.75
▲ +603.88% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Singular Genomics Systems in the last 3 months. The average price target is $21.75, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 603.88% upside from the last price of $3.09.
Current Consensus is
The current consensus among 5 investment analysts is to buy stock in Singular Genomics Systems.
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. The company manufactures G4 Instrument, a benchtop next generation sequencer to produce genetic sequencing results, as well as associated menu of consumable kits. It also offers PX Integrated Solution that combines single cell analysis, spatial analysis, genomics, and proteomics in one integrated instrument providing a versatile multiomics solution. The company has partnerships with Agilent Technologies, Dovetail Genomics, Lexogen, New England Biolab, QIAGEN, Roche, Twist Bioscience, and Watchmaker Genomics to validate their library preparation kits on the G4, as well as the Broad Institute of MIT and Harvard to connect the G4 to Terra platform, a data platform. Singular Genomics Systems, Inc. was incorporated in 2016 and is headquartered in La Jolla, California.